| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
130,214 |
119,351 |
$23.24M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
116,310 |
64,805 |
$1.44M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
51,659 |
31,044 |
$833K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
14,378 |
8,007 |
$253K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
11,475 |
6,410 |
$231K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
7,343 |
4,353 |
$223K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
11,053 |
7,043 |
$165K |
| G9920 |
Screening performed and negative |
11,634 |
6,688 |
$160K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
7,825 |
7,048 |
$153K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,922 |
1,904 |
$147K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,035 |
3,956 |
$141K |
| 92551 |
|
23,258 |
13,027 |
$116K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
4,660 |
2,622 |
$112K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,940 |
1,894 |
$96K |
| 17110 |
|
1,653 |
1,075 |
$88K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
10,528 |
5,788 |
$87K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
14,934 |
10,999 |
$78K |
| 87634 |
|
1,307 |
1,268 |
$77K |
| 11102 |
|
1,302 |
800 |
$61K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,466 |
881 |
$58K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
3,282 |
1,948 |
$55K |
| 80053 |
Comprehensive metabolic panel |
4,983 |
4,939 |
$43K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
11,913 |
6,803 |
$43K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
22,499 |
17,445 |
$38K |
| 90686 |
|
9,084 |
5,571 |
$37K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,033 |
2,027 |
$31K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,649 |
5,529 |
$27K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,561 |
1,431 |
$26K |
| 83655 |
|
2,147 |
2,131 |
$26K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,338 |
1,331 |
$25K |
| 80061 |
Lipid panel |
2,080 |
2,077 |
$24K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,455 |
767 |
$23K |
| 99173 |
|
20,245 |
12,384 |
$22K |
| 99215 |
Prolong outpt/office vis |
1,278 |
836 |
$20K |
| 90670 |
|
6,697 |
4,145 |
$20K |
| 17000 |
|
735 |
522 |
$18K |
| 87400 |
|
1,594 |
1,548 |
$18K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
290 |
164 |
$15K |
| 90648 |
|
4,704 |
2,900 |
$15K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,716 |
1,710 |
$14K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,384 |
843 |
$14K |
| 90633 |
|
4,336 |
2,497 |
$13K |
| 99188 |
|
1,167 |
688 |
$12K |
| 90723 |
|
3,083 |
1,959 |
$9K |
| 99381 |
|
407 |
272 |
$9K |
| 90677 |
|
1,345 |
840 |
$9K |
| 90651 |
|
1,651 |
951 |
$9K |
| 90698 |
|
2,971 |
1,890 |
$8K |
| 90680 |
|
2,157 |
1,382 |
$6K |
| 96127 |
|
1,489 |
901 |
$5K |
| 71046 |
Radiologic examination, chest; 2 views |
311 |
306 |
$5K |
| 85018 |
|
2,699 |
2,676 |
$5K |
| 11104 |
|
77 |
42 |
$5K |
| G9919 |
Screening performed and positive and provision of recommendations |
311 |
176 |
$5K |
| 81003 |
|
4,330 |
2,448 |
$5K |
| 0002A |
|
99 |
51 |
$5K |
| 90744 |
|
1,935 |
1,250 |
$5K |
| 85027 |
|
793 |
780 |
$5K |
| 99000 |
|
1,329 |
1,305 |
$4K |
| 90734 |
|
1,067 |
604 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
141 |
141 |
$3K |
| 81025 |
|
1,890 |
1,071 |
$3K |
| 0001A |
|
73 |
71 |
$3K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
109 |
91 |
$3K |
| 87807 |
|
229 |
226 |
$2K |
| 90710 |
|
587 |
330 |
$2K |
| 90681 |
|
820 |
558 |
$2K |
| 11100 |
|
80 |
62 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
318 |
192 |
$2K |
| 90656 |
|
434 |
317 |
$2K |
| 92588 |
|
63 |
63 |
$1K |
| 17003 |
|
222 |
161 |
$1K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
35 |
24 |
$1K |
| 99383 |
|
42 |
26 |
$1K |
| 90696 |
|
335 |
180 |
$989.44 |
| 69210 |
|
77 |
57 |
$969.95 |
| 90707 |
|
269 |
156 |
$965.14 |
| 90715 |
|
224 |
140 |
$944.82 |
| 90700 |
|
261 |
156 |
$922.62 |
| 90716 |
|
295 |
177 |
$850.20 |
| 99384 |
|
22 |
13 |
$733.00 |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
43 |
41 |
$641.21 |
| 11200 |
|
52 |
29 |
$613.63 |
| 90480 |
|
16 |
14 |
$560.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
150 |
86 |
$544.54 |
| 82043 |
|
111 |
111 |
$493.14 |
| 82570 |
|
83 |
83 |
$345.00 |
| 36415 |
Collection of venous blood by venipuncture |
2,396 |
2,326 |
$308.42 |
| 99205 |
Prolong outpt/office vis |
17 |
12 |
$248.10 |
| 86140 |
|
52 |
51 |
$226.48 |
| 80076 |
|
28 |
28 |
$211.16 |
| 85610 |
|
121 |
51 |
$187.73 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
274 |
169 |
$179.58 |
| 87081 |
|
14 |
14 |
$79.52 |
| 81001 |
|
12 |
12 |
$32.48 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
14 |
12 |
$32.25 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
673 |
660 |
$4.24 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
65 |
42 |
$1.08 |
| 3077F |
|
209 |
202 |
$0.00 |
| 3078F |
|
6,768 |
6,354 |
$0.00 |
| 3725F |
|
601 |
596 |
$0.00 |
| 1160F |
|
191 |
185 |
$0.00 |
| 1159F |
|
191 |
185 |
$0.00 |
| 90662 |
|
13 |
12 |
$0.00 |
| G0466 |
Federally qualified health center (fqhc) visit, new patient; a medically-necessary, face-to-face encounter (one-on-one) between a new patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
12 |
12 |
$0.00 |
| 3074F |
|
6,896 |
6,469 |
$0.00 |
| 3008F |
|
5,959 |
5,673 |
$0.00 |
| 1036F |
|
5,297 |
4,987 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
44 |
40 |
$0.00 |
| 3075F |
|
557 |
547 |
$0.00 |
| 3079F |
|
799 |
774 |
$0.00 |
| 3080F |
|
86 |
83 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
27 |
27 |
$0.00 |
| 3044F |
|
12 |
12 |
$0.00 |